학술논문
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Document Type
article
Author
Patrice Cacoub; Arsène Mekinian; David Saadoun; Pavel I Novikov; Savino Sciascia; Corrado Campochiaro; Olivier Fain; Ilya Smitienko; Nicolas Schleinitz; Patrick Jégo; Francesco Muratore; Carlo Salvarani; Elena Galli; Sabine Berthier; Marc Lambert; François Maurier; Isabelle Kone-Paut; Sergey Moiseev; Masataka Kuwana; Alexandre Belot; Martin Michaud; Francis Gaches; Achille Aouba; Xavier Puechal; Karim Sacre; Tiphaine Goulenok; Alessandro Tomelleri; Thomas Sené; Elena Marina Baldissera; Luigi Boiardi; Abid Awisat; Ygal Benhamou; Vahan Mukuchyan; Mathieu Vautier; Azeddine Dellal; Lucie Biard; Julie Seguier; José Hernández-Rodríguez; Olivier Espitia; Sebastien Humbert; Guillaume Denis; Nolan Hassold; Dagna Lorenzo; Helene Munoz Pons; Jean Baptiste Gaultier; Le Mouel Edwige; Antoinette Perlat; Bertrand Lioger; Jonathan Broner; Virginie Dufrost; Faten Frikha; Alexandra Audemard-Verger; Pascal Woaye-Hune; Pierre Zeminsky; Moya Alvarado; Matheus Vieira; Alberto Lo Gullo
Source
RMD Open, Vol 9, Iss 2 (2023)
Subject
Language
English
ISSN
2056-5933
Abstract
Objectives In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.Methods We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019.Results A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH